Evidence map›Paper›PMID 24637716›Full record

ArticlePloS one2014

Effects of THAP11 on erythroid differentiation and megakaryocytic differentiation of K562 cells.

Xiang-Zhen Kong, Rong-Hua Yin, Hong-Mei Ning, Wei-Wei Zheng, Xiao-Ming Dong, Yang Yang, Fei-Fei Xu, Jian-Jie Li, Yi-Qun Zhan, Miao Yu and 5 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Review
  3. The Downregulation of Both Giant HERCs,Journal of clinical medicine · 2022
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 2 countries.

Xiang-Zhen KongDepartment of Pharmaceutical Engineering, Tianjin University, Tianjin, China; Department of Biochemistry and Molecular Biology, Beijing Institute of Radiation Medicine, Beijing, China.
Rong-Hua YinDepartment of Biochemistry and Molecular Biology, Beijing Institute of Radiation Medicine, Beijing, China; State Key Laboratory of Proteomics, Beijing, China.
Hong-Mei NingDepartment of Hematopoietic Stem Cell Transplantation, Affiliated Hospital to Academy of Military Medical Sciences, Beijing, China.
Wei-Wei ZhengDepartment of Biochemistry and Molecular Biology, Beijing Institute of Radiation Medicine, Beijing, China.
Xiao-Ming DongDepartment of Pharmaceutical Engineering, Tianjin University, Tianjin, China.
Yang YangDepartment of Chemistry, Purdue University, West Lafayette, Indiana, United States of America.
Fei-Fei XuDepartment of Biochemistry and Molecular Biology, Beijing Institute of Radiation Medicine, Beijing, China.
Jian-Jie LiDepartment of Pulmonary Neoplasms Internal Medicine, Affiliated Hospital to Academy of Military Medicine Sciences, Beijing, China.
Yi-Qun ZhanDepartment of Biochemistry and Molecular Biology, Beijing Institute of Radiation Medicine, Beijing, China.
Miao YuDepartment of Biochemistry and Molecular Biology, Beijing Institute of Radiation Medicine, Beijing, China.
Chang-Hui GeDepartment of Biochemistry and Molecular Biology, Beijing Institute of Radiation Medicine, Beijing, China.
Jian-Hong ZhangDepartment of Biochemistry and Molecular Biology, Beijing Institute of Radiation Medicine, Beijing, China.
Hui ChenDepartment of Biochemistry and Molecular Biology, Beijing Institute of Radiation Medicine, Beijing, China.
Chang-Yan LiDepartment of Biochemistry and Molecular Biology, Beijing Institute of Radiation Medicine, Beijing, China; State Key Laboratory of Proteomics, Beijing, China.
Xiao-Ming YangDepartment of Pharmaceutical Engineering, Tianjin University, Tianjin, China; Department of Biochemistry and Molecular Biology, Beijing Institute of Radiation Medicine, Beijing, China; State Key Laboratory of Proteomics, Beijing, China.
Beijing Radiation Center · CNAcademy of Military Medical Sciences · CNState Key Laboratory of ProteomicsTianjin University · CNPurdue University West Lafayette · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hematopoiesis is a complex process regulated by sets of transcription factors in a stage-specific and context-dependent manner. THAP11 is a transcription factor involved in cell growth, ES cell pluripotency, and embryogenesis. Here we showed that THAP11 was down-regulated during erythroid differentiation but up-regulated during megakaryocytic differentiation of cord blood CD34+ cells. Overexpression of THAP11 in K562 cells inhibited the erythroid differentiation induced by hemin with decreased numbers of benzidine-positive cells and decreased mRNA levels of α-globin (HBA) and glycophorin A (GPA), and knockdown of THAP11 enhanced the erythroid differentiation. Conversely, THAP11 overexpression accelerated the megakaryocytic differentiation induced by phorbol myristate acetate (PMA) with increased percentage of CD41+ cells, increased numbers of 4N cells, and elevated CD61 mRNA levels, and THAP11 knockdown attenuated the megakaryocytic differentiation. The expression levels of transcription factors such as c-Myc, c-Myb, GATA-2, and Fli1 were changed by THAP11 overexpression. In this way, our results suggested that THAP11 reversibly regulated erythroid and megakaryocytic differentiation.

Indexed as

Antigens, CD34Cell DifferentiationErythroid CellsFetal BloodGene Expression RegulationHematopoiesisHematopoietic Stem CellsHeminHumansK562 CellsMegakaryocytesRepressor ProteinsRNA, MessengerTranscription FactorsAntigens, CD34HeminRepressor ProteinsRNA, MessengerTHAP11 protein, humanTranscription Factors

Identifiers

PMID24637716
PMCPMC3956667
OpenAlexW2092466788

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.